
Pelacarsen Cut Lp(a) 78%. Cardiovascular Events Did Not Fall.
In more than 8,300 people with established cardiovascular disease, pelacarsen dramatically lowered an inherited risk marker—but major cardiovascular events were virtually identical to placebo. The result challenges the simplest version of the Lp(a) hypothesis without making Lp(a) irrelevant.


















